Louisiana Administrative Code
Title 55 - PUBLIC SAFETY
Part I - State Police
Chapter 5 - Breath and Blood Alcohol Analysis Methods and Techniques
Subchapter C - Analysis of Blood and Urine for Controlled Dangerous Substances
Section I-571 - Definitions

Universal Citation: LA Admin Code I-571

Current through Register Vol. 50, No. 9, September 20, 2024

A. The following words and terms used in this Subchapter shall have the following meanings.

Aliquot-different samples from the same specimen.

Analyte-the drug or drug metabolite suspected or detected.

Chain of Custody-the accounting of the integrity of each specimen through the tracking of all individuals or agencies which may have handled the sample from the point of collection to final disposition.

Confirmation Test-a second analytical procedure to identify the presence or absence of a specific drug or drug metabolite.

Crime Laboratory-the Louisiana State Police Crime Laboratory.

Department-the Department of Public Safety and Corrections, Public Safety Services.

False Negative-not reporting an analyte which is present in the sample.

False Positive-the reporting of an analyte which is not present in the sample.

Proficiency Testing Program-performance of testing on specimens containing drugs or drug metabolites or lack of which the laboratory shall be prepared to assay in concentration ranges that allow detection of the analyte by commonly used screening techniques.

Quality Assurance-a program to ensure quality standards in all aspects of the testing process including but not limited to, specimen acquisition, chain of custody, screening and confirmation testing, and validation of analytical procedure.

Quality Control-procedures designed to assess the conduct of each step of the process for testing of drugs.

Retention Times-the time for a sample component to elute from a chromatographic column which is useful in the possible identification of that component.

Screening (Initial) Test-a test documented to indicate the possible presence of absence of a particular drug, drug class, or drug metabolite.

AUTHORITY NOTE: Promulgated in accordance with R.S. 32:663.

Disclaimer: These regulations may not be the most recent version. Louisiana may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.